WAVE LIFE SCIENCES LTD. (NASDAQ:WVE) Files An 8-K Results of Operations and Financial ConditionItem 2.02
On March12, 2018, Wave Life Sciences Ltd. (the “Company”) announced its financial results for the quarter and year ended December31, 2017. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
|Item 2.02||Regulation FD Disclosure.|
From time to time, the Company presents and/or distributes slides and presentations to the investment community to provide updates and summaries of its business. On March12, 2018, the Company updated its corporate presentation, which is available on the “For Investors& Media” section of the Company’s website at http://ir.wavelifesciences.com/. This presentation is also furnished as Exhibit 99.2 to this Current Report on Form 8-K.
The information in this report furnished to Items 2.02 and 7.01 shall not be deemed “filed” for the purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished to Items 2.02 and 7.01 of this report.
|Item 2.02||Financial Statements and Exhibits.|
The following exhibits relating to Items 2.02 and 7.01 shall be deemed to be furnished, and not filed:
Wave Life Sciences Ltd. ExhibitEX-99.1 2 d540276dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Wave Life Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Business Update Initiated three clinical trials in 2017 and on track to deliver three additional development programs in 2018 Neurology pipeline growing; candidate in spinocerebellar ataxia type 3 to be named by year end 2018 CAMBRIDGE,…To view the full exhibit click
About WAVE LIFE SCIENCES LTD. (NASDAQ:WVE)
WAVE Life Sciences Ltd. is a preclinical biopharmaceutical company. The Company focuses on developing its synthetic chemistry platform to develop and commercialize a pipeline of nucleic acid-based therapeutics. It develops nucleic acid therapeutics that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. Its advanced therapeutic programs are in Huntington’s disease, duchenne muscular dystrophy (DMD) and inflammatory bowel disease (IBD). In Huntington’s disease, it has programs that target HTT SNP-1 and HTT SNP-2; in DMD, it targets Exon 51, and in IBD, it targets SMAD7. It has selected lead product candidates in its programs targeting HTT SNP-1 and Exon 51. It has late-stage discovery programs in epidermolysis bullosa simplex, in which it targets KRT14 SNP-1 and KRT14 SNP-2, and in DMD, in which it is focused on an additional DMD target, AcRIIb.